1655 related articles for article (PubMed ID: 8673048)
41. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
[TBL] [Abstract][Full Text] [Related]
42. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality.
Robin M; Guardiola P; Dombret H; Baruchel A; Esperou H; Ribaud P; Devergie A; Gluckman E; Socié G
Bone Marrow Transplant; 2003 May; 31(10):877-87. PubMed ID: 12748664
[TBL] [Abstract][Full Text] [Related]
43. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor.
Chim CS; Lie AK; Liang R; Au WY; Kwong YL
Bone Marrow Transplant; 2007 Aug; 40(4):339-47. PubMed ID: 17572712
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Matsuyama T; Kojima S; Kato K
Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
[TBL] [Abstract][Full Text] [Related]
45. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
48. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
Mehta J; Powles R; Sirohi B; Treleaven J; Kulkarni S; Saso R; Tait D; Singhal S
Bone Marrow Transplant; 2002 May; 29(10):853-9. PubMed ID: 12058235
[TBL] [Abstract][Full Text] [Related]
49. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
50. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
51. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
52. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin.
Bacigalupo A; Oneto R; Bruno B; Soracco M; Lamparelli T; Gualandi F; Occhini D; Raiola A; Mordini N; Berisso G; Bregante S; Dini G; Lombardi A; Lint MV; Brand R
Bone Marrow Transplant; 1999 Sep; 24(6):653-9. PubMed ID: 10490732
[TBL] [Abstract][Full Text] [Related]
53. Slow response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. The Leukemia Working Party of the European Group of Bone Marrow Transplantation (EBMT).
Niederwieser D; Granena A; Hermans J; Kolb HJ; Zwaan F; Gratwohl A
Bone Marrow Transplant; 1992 Jun; 9(6):439-43. PubMed ID: 1628128
[TBL] [Abstract][Full Text] [Related]
54. Outcome of acute lymphoblastic leukaemia in Danish children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched unrelated donor grafts.
Lausen BF; Heilmann C; Vindeløv L; Jacobsen N
Bone Marrow Transplant; 1998 Aug; 22(4):325-30. PubMed ID: 9722066
[TBL] [Abstract][Full Text] [Related]
55. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children.
Parsons SK; Castellino SM; Lehmann LE; Eickhoff CE; Tarbell NJ; Sallan SE; Weinstein HJ; Billett AL
Bone Marrow Transplant; 1996 May; 17(5):763-8. PubMed ID: 8733695
[TBL] [Abstract][Full Text] [Related]
56. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT).
Mandelli F; Labopin M; Granena A; Iriondo A; Prentice G; Bacigalupo A; Sierra J; Meloni G; Frassoni F; Goldman J
Bone Marrow Transplant; 1994 Aug; 14(2):293-8. PubMed ID: 7994245
[TBL] [Abstract][Full Text] [Related]
57. Cyclosporine-A as GVHD prophylaxis in allogeneic BMT for childhood acute leukemia. AIEOP-BMT group.
Pession A; Locatelli F; Zecca M; Rondelli R; Prete A; Bonetti F; Paolucci G
Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S50-2. PubMed ID: 9630326
[TBL] [Abstract][Full Text] [Related]
58. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
[TBL] [Abstract][Full Text] [Related]
59. Bone marrow transplantation for leukaemia in Europe.
Gratwohl A; Hermans J; Lyklema A; Zwaan FE
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):353-60. PubMed ID: 2480274
[TBL] [Abstract][Full Text] [Related]
60. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
